Tags

Type your tag names separated by a space and hit enter

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals.
Euro Surveill. 2015 Jan 15; 20(2)ES

Abstract

While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case-control study to estimate IVE against hospitalised laboratory-confirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09.

Authors+Show Affiliations

EpiConcept, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25613779

Citation

Rondy, M, et al. "2012/13 Influenza Vaccine Effectiveness Against Hospitalised Influenza A(H1N1)pdm09, A(H3N2) and B: Estimates From a European Network of Hospitals." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 20, no. 2, 2015.
Rondy M, Launay O, Puig-Barberà J, et al. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. Euro Surveill. 2015;20(2).
Rondy, M., Launay, O., Puig-Barberà, J., Gefenaite, G., Castilla, J., de Gaetano Donati, K., Galtier, F., Hak, E., Guevara, M., Costanzo, S., & Moren, A. (2015). 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 20(2).
Rondy M, et al. 2012/13 Influenza Vaccine Effectiveness Against Hospitalised Influenza A(H1N1)pdm09, A(H3N2) and B: Estimates From a European Network of Hospitals. Euro Surveill. 2015 Jan 15;20(2) PubMed PMID: 25613779.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. AU - Rondy,M, AU - Launay,O, AU - Puig-Barberà,J, AU - Gefenaite,G, AU - Castilla,J, AU - de Gaetano Donati,K, AU - Galtier,F, AU - Hak,E, AU - Guevara,M, AU - Costanzo,S, AU - ,, AU - Moren,A, Y1 - 2015/01/15/ PY - 2015/1/24/entrez PY - 2015/1/24/pubmed PY - 2015/4/18/medline JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill. VL - 20 IS - 2 N2 - While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case-control study to estimate IVE against hospitalised laboratory-confirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/25613779/2012/13_influenza_vaccine_effectiveness_against_hospitalised_influenza_A_H1N1_pdm09_A_H3N2__and_B:_estimates_from_a_European_network_of_hospitals_ L2 - http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21011 DB - PRIME DP - Unbound Medicine ER -